Abstract: Restenosis remains a major limitation of corortary angioplasty in spite of major advances in techniques and technology. Recent studies have demonstrated that ionizing radiation may limit the degree of this problem. Gamma radiation has been shown to be effective in reducing in stent restenosis in humans, and beta radiatio~ following encouraging results in animals has been shown to be feasible in humans. The objective of this study was to assess the feasibility of a 5 F non-centered catheter to deliver beta radiation emitting seeds to the lesion site post angioptasty and its effect on restenosis. Following successful angioplasty, patients were randomized to treatment with 12.14 or 16 Gy at the angioplasty site. This was delivered with a 5 t" non-centered catheter. Twelve beta radiation emittfi~g seeds (g~ were delivered to an ama Key Words: Beta Radiation 9 Restenosis. Coronary angioplasty 3 cm in length to cover the angioplasty site. Angiographic folIow-up was performed at 6 months. Baseline and follow-up angiograms were performed by blinded investigators at a core laboratory. This interim report comprises the first 35 patients to complete 6-month angiographic follow-up. Thme were no major radiation incidents. Four patients had evidence of angiographic restenosis. The MLD (mm) and percent stenosis were 0.77 _-2-0.27/72. 
3 cm in length to cover the angioplasty site. Angiographic folIow-up was performed at 6 months. Baseline and follow-up angiograms were performed by blinded investigators at a core laboratory. This interim report comprises the first 35 patients to complete 6-month angiographic follow-up. Thme were no major radiation incidents. Four patients had evidence of angiographic restenosis. The MLD (mm) and percent stenosis were 0.77 _-2-0.27/72.5 • 8.6 pre angioplasty, 2.08 _+ 0.4/25.7 • 9.8 post angioplasty and radiation and 2.05 • 0.59/25.7 _+_ 19.8 at follow-up respectively. Conclusion: Beta radiation can be feasibly and safely delivered post coronary angioplasty witb a very encouraging reduction 017 restenosis. T he application of intracoronary brachytherapy to the problem of post angioplasty restenosis represents a potential solution to what remains a vexing problem. Progress in refinement of technology and improvement of techniques have allowed interventional cardiologists to tackle increasingty challenging situations successfully. In spite of this, the multiple attempts to limit the problem of restenosis have met with consistent disappointment [7] . Following numerous encouraging animal studies [1, [15] [16] [17] , intracoronary gamma radiation has recentIy been demonstrated to be feasible in humans [3] and in a small, randomized trial to limit the problem of in-stent restenosis [13] . Although numerous beta radiation emitting systems have been used in animal studies, only a single system of a baUoon centered 90-yttrium (o0y) wire for post angioplasty use, has been reported in humans in a small feasibility trial [14] .
Wirksamkeil der Be|astrahlung zur Priivenfion der Reslenose nach PTCA: Ein Zwischenbericht der BERT-StudŸ
The objective of the Beta Energy Restenosis Trial (BERT) was to assess the fe.asibility and safety of 3 prescribed doses of beta radiation delivered post angioplasty to the coronary artery by means of a non-ccntered 5 French (F) catheter-based system for reducing restenosis in non-stented coronary arteries, and to determine its effect on the restenosis process.
Methods
In this interim analysis of the multicenter randomized open trial, 14 patients were recruited at Emory University Hospital, 6 at Rhode Island Hospital and 16 at the Institut de Cardiologie de Montreal.
The protocol was approved by the institutional review board of each participating institution. Written informed consent was obtained from each patient prior to enrolhnent and randomization in the trial.
Selection of Patients
Patients aged between 18 and 80 years with angina of proven ischemia on laboratory testing due to undergo planned balloon angioplasty treatment of a single coronary lesion in a native coronary artery, were eligible for inclusion in the study. The target lesions were required to llave between 60 and 99% diameter stenosis.
Patients were excluded for 1. evidence of a myocardial infarction within the 3 days p¡ to the procedure, 2. contraindication to aspirin, 3. left ventricu[ar ejection fraction less than 40%, 4. serum creatinine greater than 2.0, 5. anticipated difficulty with follow-up, 6. tire threatening coexisting illness, 7. women of child bearing pote ntial, 8. severe peripheral vascular disease, 9. unprotected left main coronary artery disease, 10. presence of thrombus, 11. past chest radiotherapy, 12. lesion angled > 45 degrees, 13. intraprocedural angiographic evidence of thrombus, spasm of dissection, 14. unsatisfactory PTCA result requiring stent implantation.
Procedure
The patients were treated with 325 mg of aspirin, intravenous nitroglycerin and heparin in doses adequate to maimain ah activated clotting time of at least 300 seconds throughout the procedure. Baseline coronary angiography was performed and followed by YFCA according to standard clinical practice. Fifteen minutes after a successful trfCA, as determined by residual stenosis of < 50% and an increase of lumen diameter of > 20%, patients were randomized to receive 12, 14, or 16 Gy as calculated at 2 mm from the center line. Procedural success was determined by angiography. A 5 F delivery catheter (Novoste Corp, Norcross, Georgia) was positioned at the site of PTCA with 2 markers separated by 3 cm used for positioning of the catheter across the angioplasty site (I¡ 1). The guidewire was removed and a 3 cm long train of 90-strontium/yttrium (9~ seeds was positioned between the aforementioned markers using fluoroscopic visualization. The seeds remained in place for the period determined to deliver the prescribed dose at 2 mm from the ]uminal center line without regard to any curvature of the source train ( Figure 2 ). Following irradiation, angiography was repeated. Al1 cincangiograms were performed following intracoronary nitroglycerin.
Two to 4 hours after the procedure the femoral sheaths were removed. Electrocardiograms were performed immediately and the next morning. Creatine kinase and MB fraction were measured prior to the procedure, at its completion and 8 and 16 hours post procedure. Ir the procedure was uncomplicated, patients were diseharged the next day with instructions to continue 325 mg aspirin indefinitely, and if a stent was implanted, ticlopidine 250 mg twice daily for 15 days.
Radiation Details
The radiation system used in this study consisted of a series of 12 independent cylindrical seeds delivered as a train in a non-centered delivew catheter. Each seed of l-ferz 1998;23:356-61 (Nr. 6) 2.5 mm length is composed of radioactive materials (90 SI q sintered into ceramic, sealed within a cylindrical stainless steel capsule. The length of the source train chosen was calculated for treatment over 30 mm, allowing for 5 mm proximal and distal to the angioplasty site when using a standard 20 m m balloon. The prescribed doses of 12, 14, and 16 G y at 2 mm from the center of the catheter resulted in intracoronary dwell times of 158 to 218 seconds based on source activity and GafChromic Dosimetry Media m e a s u r e m e n t s as previously described [6] . The delivery system is a non-centered 5 F device with potentiat for variation from the prescribed radiation dose to that deljvered to different sites of the arterial wall. The delivery catheter is non-occlusive in the target coronary vessel and therefore no dose fractionation is necessary of r e c o m m e n d e d .
Quantitative Angiographic Analysis
Angiography was p e r f o r m e d in 2 orthogonal projections pre and post angioplasty. These same views were repeated following radiation therapy and at follow-up. Decisions regarding inclusion and procedural success were made using an online quantitative angiographic system. Atl procedural and follow-up angiograms were forwarded to the E m o r y University Angiographic Core L a b o r a t o r y for interpretation and m e a s u r e m e n t by i n d e p e n d e n t observers according to a previously validated method [8] line, post procedure and at follow-up. Acute gain (mm) was defined as MLD post angioplasty less the MLD pre angioplasty. Late loss was defined as MLD post angioplasty less MLD at follow-up. Loss index was defined as late loss divided by the acute gain. Restenosis was defined as > 50% diameter stenosis at follow-up.
Follow-Up
Patients were contacted by telephone monthly. Clinical assessment was performed 3-monthly. Angiographic follow-up was performed at 6 months. Follow-up angiography recorded less than 5 months after the procedure was excluded unless restenosis had occurred.
] h e primary endpoint was the technical success of the irradiation treatment as defined by the ability to pass the closed end 5 F radiation catheter to the lesion site as verified by fluoroscopy and recorded on fihn, the ability to transfer the radiation source to the distal end of the delivery catheter and return it to the transfer device.
Secondary clinical endpoints were death, myocardial infarction, coronary bypass surgery, target lesion revascularization and restenosis as defined by MLD < 50% at fotlow-up.
Statistical A nalysis
Alt values are provided as proportions o r a s mean +_ standard deviation. Comparisons of post procedural with 6-month follow-up results were done using the paired t-test. Statistical significance was indicated by p < 0.05 on a 2-tailed test,
Results
Of 43 patients recruited for inclusion in the study between January 1996 and April 1997. Five patients were excluded following unsatisfactory results with angioplastv alone, requiring stent lmptantation. Thirty-eight underwent randomization for radiation therapy. One patient was unavailable for follow-up and therefore was excluded from this interim analysis. The radiation catheter and seeds were deployed and the prescfibed dose delivered to all but 2 patients. In 1 patient, due to severe vascular tortuosity, the detivery catheter could not be advanced to the lesion site. In the other, due to obstruction of the delivery catheter the radioactive seeds could not be transferred in the catheter. The patients' baseline clinical characteristics ate shown in Table 1 .
Procedure and Early Clinical Outcome
This interim analysis includes the first 35 patients who underwent successful angioplasty, radiation therapy and 6-month follow-up ( Table 2 ).
The radiation therapy was well tolerated by all the patients with no major complications during the treatments. None of the treatments required fractionation nor were they interrupted prematurely. In a single pati- 
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ent, due to severe catcification, the deIivery catheter could not cover the entire lesion. In another patient, following overtightening of the Tuohy-Borst valve, a kink in the hydrautic system used for seed deployment, prevented the return of the seeds to the protš housing. The entire system was immediately removed and deposired into the awaiting Lucite radioprotective box with no increased radiation exposure. In a further patient the distal gold marker was not retrieved into the protective housing at the completion of the procedure. Al1 the radioactive seeds, however, were safely in the radioprotective housing. There were no acute radiation events.
Following angioplasty and radiation therapy 3 patients suffered acute vessel closure, requiring re-PTCA and stent implantation. Two further patients required stent implantation due to worsening of di ssections that were present post PTCA but pre-radiation therapy.
Clinical and Angiographic Fotlow-Up
~lhe MLD (mm) and percent stenosis were 0.77 • 0.27/72.5 _+ 8.6 pre angioplasty, 2.08 _+ 0.4/25.7 • 9.8 post angioplasty and radiation and 2.05 _+ 0.59/25.7 _+ 19.8 at follow-up respectively (Table 3) .
Four of the 35 patient, cohort presented with angiographic restenosis at the treated site. PTCA was perfor-. med in 1 case for angiographic restenosis at the sarne site. Two patients underwent coronary artery bypass surgery, one at 4 months although the target lesion had been stented and was patent.
Of the 5 patients treated with stents initially none showed angiographic restenosis, the patients with angiographic restenosis were from the non-stented cohort. There were no deaths of myocardial infarctions. No aneurysms were detected angiographically.
Discussion
The introduction of intracoronary brachytherapy asa potential solution for restenosis has led to encouragement in an otherwise disappointing field. Following probucol [11] , itis only the second treatment that appears to reduce the post PTCA restenosis tate, and as opposed to probucol, it requires no pretreatment. This interim report of the multicenter BERT study demonstrates the feasibility and short4erm safety of applying beta radiation using a non-centered 5 F delivery catbeter, for the prevention of restenosis. In spite of 2 minor catheter incidents, no serious radiation events occurred in the short to medium term. The maintenance of the acute gain over the follow-up period, with minimal late loss anda relatively Iow angiographic restenosis rate ate indicative of the potential for this technique and dispel some of the reservations regarding the effectiveness of beta radiation due to its redª penetrance and to the treatment timing [12 I . This is supported by the low requirement for target l esion and vessel revascu]arization.
The theoretical concern of radiation catheter edge restenosis due to lower doses causing increased proliferation was not manifest in this study. At the prescribed doses no aneurysms were evident as have been reported with the use of a non-centered gamma radiation system ª higher doses [3] .
The 9~ isotope combination with its prolonged hall life of 28 years [6] , allows for the use of the same source seeds over a prolonged period and limits the alnount of source transfers required resulting in an overall decreased personnel radiation risk.
Limitations of the Smdy
This study represents an interim report of the larger BERT feasibility study and therefore is not powered adequately to provide significant results regarding restenosis and revascularization requirement. It is also a non-controlled study limiting the application of the restenosis results. The follow-up provides important data regarding short to intermediate term complications, however, this must be viewed in the light that significantly higher doses of radiation applied to larger tissª arcas, when used for treatment of neoplasms, resulted in ah increased risk of coronary artery disease over the much longer term of 5 to 20 years [41. In spite of this, the safety of brachytherapy when used for keloid [2, 9] and heterotopic bone formation [5] has been confirmed for periods of longer than 20 years and furthermore the safety of peripheral vascular brachytherapy has been demonstrated during a 6-year follow-up peri-
od [m],

Conclusion
This interim analysis of the BERT smdy demonstrates the feasibility and short and medium term safety of this non-centered 5 F device for delivering beta radiation to the vessel wall post angioplasty. Larger randomized and longer term studies ate required to provide the power to conclusively demonstrate that beta radiation is effective in safely reduciug restenosis post angioplasty.
